Karnataka

Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world. We are the 7th largest generic pharmaceutical company globally with more than 12,000 employees and estimated sales of approximately $3 billion. Our fully integrated operation is comprised of four lines of business: Global Generics; Apobiologix; Global Active Pharmaceutical Ingredients (API); and ApoPharma (Innovative Products).

Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.  Each day, our employees around the world work together for patients – it drives everything we do.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
P.Mounika*, Sanjit, Abhishek pandey, Dilraj Yadav
Gautham College of Pharmacy,
Bangalore – 560032

ABSTRACT
Objective: The objective of the present study was to develop Bilayered tablets of Nifedipine and atenolol. Bilayered tablet contains two layers. We can formulate first layer into immediate release and second layer into sustained release for desired action. Nifedipine have half-life 2hrs make the drug suitable for immediate release. Atenolol have half-life 6-7hrs make the drug suitable for sustained release.
Methods: In this formulation using super disintegrants for immediate release, acacia and ethyl cellulose as a polymers for sustained release. Tablets were prepared by wet granulation method. In this study Bilayered tablets of Nifedipine and Atenolol tablets were evaluated for weight variation, hardness, thickness, drug content and In-vitro studies.
Results: Bi-layer tablet is suitable for sequential release of two drugs in combination, separate to incompatible substances and also for immediate release as initial dose and sustained release as maintenance dose. In Immediate release formulation, IR-F-3 formulation gives 98% release within 15min. For sustained effect SR-F-3, SR-F-1 gives 98% release within 8-9hrs. SR-F-2 gives 99% release within 10-11hrs for a longer period of time.
Conclusion: The combination of IF-3 and SR-F-2 suitable for formulation. This formulation is used for Bilayered tablet to combine with sustained released tablet. The evaluation parameters were estimated.

Working in Himalayas means to learn and grow continuously.Opportunities to work on the finest ever products in the herbal space, competitive salaries and excellent benefits. We offer challenging assignments, a world class working environment, professional management and ample prospects to train and learn along with exceptional rewards.

Post : Research Associate

"We cannot compare straight away with US or Europe and say that these should be community Pharmacy and they are lagging behind. I would say that Yes! we have to improve our services and role as Pharmacist in the community pharmacy that is more important and for that knowledge is important.

Interview of Prof. Dr. B.

Farooqia College of Pharmacy, Mysore was started in the year 1980 with D.Pharm Course and in 1992 with B.Pharm course. It has an inviable track record of success and progress. In Karnataka it has its own reputation for discipline, efficiency and standards.

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries. They have helped over 800 clients to develop and launch some of the most important drugs and devices of our time-helping people live better and healthier lives everywhere in the world.

Post : Regulatory Affairs Associate

Teva is a global pharmaceutical leader and the world’s largest generic medicines producer, committed to improving health and increasing access to quality health solutions worldwide.  Our employees are at the core of our success, with colleagues in over 80 countries delivering the world’s largest medicine cabinet to 200 million people every day. We offer a uniquely diverse portfolio of products and solutions for patients and we’ve built a promising pipeline centered around our core therapeutic areas.

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B).